

# Clinical Policy: Artificial Retina

Reference Number: CA.CP.MP.349

Last Review Date: 6/22

[Coding Implications](#)

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

## Description

The Argus II Retinal Prosthesis System was approved by the United States Food and Drug Administration (FDA) under the humanitarian device exemption (HDE) application in February 2013. This system is intended to provide electrical stimulation of the retina to induce visual perception in patients with severe to profound retinitis pigmentosa (RP).

## Policy/Criteria

- I. It is the policy of California Health and Wellness that the Argus II Retinal Prosthesis System is medically necessary under the FDA HDE for the patients with severe to profound RP who meet the following criteria:
  - A. Adults, age  $\geq$  25 years
  - B. Bare light or no light reception in both eyes with evidence of intact inner layer retina function
  - C. Previous history of useful form vision
  - D. Aphakic or pseudophakic or the if phakic, the natural lens will be removed during the implant procedure
  - E. Patients must be willing to participate in the recommended post implant clinical follow-up, device fitting and visual rehabilitation
- II. It is the policy California Health and Wellness that the Argus II Retinal Prosthesis System is not medically necessary for any other circumstances than those specified above.

## Background

RP includes a group of inherited conditions that cause progressive retinal degeneration and affect the photoreceptors and retinal pigment epithelium. Loss of visual field is progressive, starting in the midperiphery and progressing more peripherally, resulting in a constricted visual field. Although there is no cure for RP, treatments are available for managing some aspects of its clinical manifestations. New treatments, involving gene therapy, transplantation, and implanted electrical devices, are in active development.

The Argus II Retinal Prosthesis System is a device implanted in and on the eye, which electrically stimulates the retina. This system includes a small video camera, a transmitter mounted on a pair of eyeglasses, a video processing unit and an implanted retinal prosthesis or artificial retina. This device converts the video images captured from the video camera into a series of small electrical impulses that are wirelessly transmitted to an array of 60 electrodes on the retina. While the Argus II Retinal Prosthesis System will not restore vision to patients, it replaces the function of degenerated cells in the retina and may improve a patient's ability to perceive images, detect light and dark in the environment and it may help them in identifying the location or movement of objects or people.

## CLINICAL POLICY

### Artificial Retina

Studies and clinical trials have noted that Argus II Retinal Prosthesis System has an acceptable risk profile and is a beneficial therapy for profoundly blind patients with RP. They have also shown that individuals implanted with this device were able to perform a motion detection task they could not do with their native vision, confirming that electrical stimulation of the retina provides spatial information from synchronized activation of multiple electrodes.

After an FDA-convened panel of 19 experts voted unanimously that the benefits outweighed the risks of the Argus II System, the FDA approved the System for market under the Humanitarian Device Exemption in the United States.

### Coding Implications

This clinical policy references Current Procedural Terminology (CPT®). CPT® is a registered trademark of the American Medical Association. All CPT codes and descriptions are copyrighted 2017, American Medical Association. All rights reserved. CPT codes and CPT descriptions are from the current manuals and those included herein are not intended to be all-inclusive and are included for informational purposes only. Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

CPT® Codes	Description
0100T	Placement of a subconjunctival retinal prosthesis receiver and pulse generator, and implantation of intra-ocular retinal electrode array, with vitrectomy
0472T	Device evaluation, interrogation, and initial programming of intra-hyphenocular retinal electrode array (eg, retinal prosthesis), in person, with iterative adjustment of the implantable device to test functionality, select optimal permanent programmed values with analysis, including visual training, with review and report by a qualified health care professional
0473T	Device evaluation and interrogation of intra-hyphenocular retinal electrode array (eg, retinal prosthesis), in person, including reprogramming and visual training, when performed, with review and report by a qualified health care professional

HCPCS Codes	Description
C1841	Retinal prosthesis, includes all internal and external components
C1842	Retinal prosthesis, includes all internal and external components; add-hyphenon to C1841
L8608	Miscellaneous external component, supply or accessory for use with the argus ii retinal prosthesis system

### ICD-10-CM Diagnosis Codes that Support Coverage Criteria

## CLINICAL POLICY

### Artificial Retina

ICD-10-CM Code	Description
H35.52	Pigmentary retinal dystrophy

Reviews, Revisions, and Approvals	Date	Approval Date
Policy Adopted from Health Net NMP#349 Artificial Retina	6/17	
Added references	6/18	6/18
Added CPT and HCPCS codes and references	6/19	6/19
Reviewed, no changes	6/20	6/20
Updated references, no change	6/21	6/21
Updated references, no change	6/22	6/22

### References

1. Ahuja AK, Dorn JD, Caspi A, et al. Blind subjects implanted with the Argus II retinal prosthesis are able to improve performance in a spatial-motor task. *Br J Ophthalmol.* 2011;95(4):539-543.
2. American Academy of Ophthalmology (AAO). Microelectronic retinal implants. AAO Rapid Clinical Report. San Francisco, CA: AAO; August 2000.
3. Ang M, Tan D. Anterior segment reconstruction with artificial iris and Descemet membrane endothelial keratoplasty: A staged surgical approach. *Br J Ophthalmol.* 2021 Feb 26 [Online ahead of print].
4. Asher A, Segal WA, Baccus SA, et al. Image processing for a high-resolution optoelectronic retinal prosthesis. *IEEE Trans Biomed Eng.* 2007;54(6 Pt 1):993-1004.
5. Barry MP, Dagnelie G; Argus II Study Group. Use of the Argus II retinal prosthesis to improve visual guidance of fine hand movements. *Invest Ophthalmol Vis Sci.* 2012;53(9):5095-5101.
6. Cheng DL, Greenberg PB, Borton DA. Advances in retinal prosthetic research: A systematic review of engineering and clinical characteristics of current prosthetic initiatives. *Curr Eye Res.* 2017;42(3):334-347.
7. Cheng DL, Greenberg PB, Borton DA. Advances in retinal prosthetic research: A systematic review of engineering and clinical characteristics of current prosthetic initiatives. *Curr Eye Res.* 2017;42(3):334-347.
8. Chiang A, Haller JA. Vitreoretinal disease in the coming decade. *Curr Opin Ophthalmol.* 2010;21(3):197-202.
9. Chuang AT, Margo CE, Greenberg PB. Retinal implants: A systematic review. *Br J Ophthalmol.* 2014;98(7):852-856.
10. Dorn JD, Ahuja AK, Caspi A, et al. The Detection of Motion by Blind Subjects With the Epiretinal 60-Electrode (Argus II) Retinal Prosthesis. *JAMA Ophthalmol.* 2013 Feb;131(2):183-9.
11. Duncan JL, Richards TP, Arditi A, et al. Improvements in vision-related quality of life in blind patients implanted with the Argus II Epiretinal Prosthesis. *Clin Exp Optom.* 2017;100(2):144-150.

## CLINICAL POLICY

### Artificial Retina

12. Endo T, Fujikado T, Hirota M, et al. Light localization with low-contrast targets in a patient implanted with a suprachoroidal-transretinal stimulation retinal prosthesis. *Graefes Arch Clin Exp Ophthalmol*. 2018;256(9):1723-1729.
13. Farvardin M, Afarid M, Attarzadeh A, et al. The Argus-II retinal prosthesis implantation; from the global to local successful experience. *Front Neurosci*. 2018;12:584.
14. Garcia S, Petrini K, Rubin GS, et al. Visual and non-visual navigation in blind patients with a retinal prosthesis. *PLoS One*. 2015;10(7):e0134369.
15. Garg S. Retinitis pigmentosa: Treatment. UpToDate [online serial]. Waltham, MA: UpToDate; reviewed July 2013; May 2017.
16. Garg S. Retinitis pigmentosa: Treatment. UpToDate. Updated May 12, 2015.
17. Gekeler F, Zrenner E, Bartz-Schmidt KU. Ocular electrical stimulation: Therapeutic application and active retinal implants for hereditary retinal degenerations. *Ophthalmologe*. 2015;112(9):712-719.
18. Ghaffari R, Aldave AJ, Al-Hashimi S, Miller KM. Complications of cosmetic artificial iris implantation and post explantation outcomes. *Am J Ophthalmol*. 2021 Jan 22 [Online ahead of print].
19. Golden JR, Erickson-Davis C, Cottaris NP, et al. Simulation of visual perception and learning with a retinal prosthesis. *J Neural Eng*. 2019;16(2):025003.
20. Hayes. News Government. FDA Approves First Retinal Implant for Adults with Rare Genetic Eye Disease. February 19, 2013.
21. Ho AC, Humayun MS, Dorn JD, et al; Argus II Study Group. Long-term results from an epiretinal prosthesis to restore sight to the blind. *Ophthalmology*. 2015;122(8):1547-1554.
22. Humayun MS, Dorn JD, da Cruz L, et al; Argus II Study Group. Interim results from the international trial of Second Sight's visual prosthesis. *Ophthalmology*. 2012;119(4):779-788.
23. Kotecha A, Zhong J, Stewart D, da Cruz L. The Argus II prosthesis facilitates reaching and grasping tasks: A case series. *BMC Ophthalmol*. 2014;14:71.
24. Lee PJ. ARMD, retinal electronic prosthesis and RPE transplantation. *eMedicine Ophthalmology Topic 763*. Omaha, NE: eMedicine.com; updated October 4, 2004.
25. Luo YH, da Cruz L. A review and update on the current status of retinal prostheses (bionic eye). *Br Med Bull*. 2014;109:31-44.
26. Luo YH, da Cruz L. The Argus<sup>®</sup> II retinal prosthesis system. *Prog Retin Eye Res*. 2016;50:89-107.
27. Pei ZJ, Gao GX, Hao B, et al. A cascade model of information processing and encoding for retinal prosthesis. *Neural Regen Res*. 2016;11(4):646-651.
28. Rizzo S, Belting C, Cinelli L, et al. The Argus II Retinal Prosthesis: 12-month outcomes from a single-study center. *Am J Ophthalmol*. 2014;157(6):1282-1290.
29. Sabbah N, Authie CN, Sanda N, et al. Importance of eye position on spatial localization in blind subjects wearing an Argus II retinal prosthesis. *Invest Ophthalmol Vis Sci*. 2014;55(12):8259-8266.
30. Second Sight Medical Products. Argus™ II Retinal Stimulation System Feasibility Protocol. ClinicalTrials.gov. Identifier NCT00407602. Bethesda, MD: National Institutes of Health; updated August 28, 2008.

## CLINICAL POLICY

### Artificial Retina

31. Seitz IP, Achberger K, Liebau S, Fischer MD. Stem cells for retina replacement. *Klin Monbl Augenheilkd.* 2016;233(12):1350-1356.
32. Stronks HC, Dagnelie G. The functional performance of the Argus II retinal prosthesis. *Expert Rev Med Devices.* 2014;11(1):23-30.
33. U.S. Food & Drug Administration. The Argus II Retinal Prosthesis System. February 13, 2013. Available at: [https://www.accessdata.fda.gov/cdrh\\_docs/pdf11/h110002b.pdf](https://www.accessdata.fda.gov/cdrh_docs/pdf11/h110002b.pdf)
34. U.S. Food and Drug Administration (FDA). FDA approves first retinal implant for adults with rare genetic eye disease. *FDA News.* Silver Spring, MD: FDA; February 14, 2013.
35. Vandepier M. Technology Brief: Argus II Retinal Prosthesis System for peripheral retinal degeneration. Health Policy Advisory Committee on Technology (HealthPACT). Australian Safety and Efficacy Register of New Interventional Procedures – Surgical (ASERNIP-S). Herston, QLD: Queensland Department of Health; November 2013.
36. Weiland JD, Cho AK, Humayun MS. Retinal prostheses: Current clinical results and future needs. *Ophthalmology.* 2011;118(11):2227-2237.
37. Weiland JD, Humayun MS. Retinal prosthesis. *IEEE Trans Biomed Eng.* 2014;61(5):1412-1424.

### **Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan

## CLINICAL POLICY

### Artificial Retina

retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

**Note: For Medicaid members,** when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

**Note: For Medicare members,** to ensure consistency with the Medicare National Coverage Determinations (NCD) and Local Coverage Determinations (LCD), all applicable NCDs, LCDs, and Medicare Coverage Articles should be reviewed prior to applying the criteria set forth in this clinical policy. Refer to the CMS website at <http://www.cms.gov> for additional information.

©2016 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.